公开(公告)号：US20140221406A1

公开(公告)日：2014-08-07

申请号：US14118200

申请日：2012-05-17

Applicant: Wang Shen ,  Wei Xiao ,  Jack Maung ,  Aimin Zhang ,  Xiaoling Zheng ,  Zhenzhong Wang ,  Qingming Guo ,  Yingguang Li

Inventor： Wang Shen ,  Wei Xiao ,  Jack Maung ,  Aimin Zhang ,  Xiaoling Zheng ,  Zhenzhong Wang ,  Qingming Guo ,  Yingguang Li

IPC: C07D405/12 ,  C07D493/04

CPC classification number: C07D405/12 ,  C07D493/04

Abstract: The invention provides quinazoline-7-ether derivatives, particularly 4-anilinyl-6-butenamido-quinazoline-7-ether derivatives that are inhibitors of the receptor protein tyrosine kinases (RTK). The compounds are useful in the treatment of diseases and disorders where RTK activity is implicated such as a hyperproliferative diseases (e.g., cancer). Also provided are methods of preparation of the quinazoline derivatives and methods of use as therapeutic agents alone or in a drug combination.

Abstract translation: 本发明提供了喹唑啉-7-醚衍生物，特别是作为受体蛋白酪氨酸激酶（RTK）抑制剂的4-苯乙烯基-6-丁烯酰氨基 - 喹唑啉-7-醚衍生物。 所述化合物可用于治疗涉及RTK活性的疾病和病症，例如过度增殖性疾病（例如癌症）。 还提供了制备喹唑啉衍生物的方法和单独使用或作为药物组合用作治疗剂的方法。

公开(公告)号：US20120196833A1

公开(公告)日：2012-08-02

申请号：US13380808

申请日：2010-07-02

Applicant: Wang Shen ,  Aimin Zhang ,  Junfa Fan ,  Xiaoling Zheng

Inventor： Wang Shen ,  Aimin Zhang ,  Junfa Fan ,  Xiaoling Zheng

IPC: A61K31/675 ,  A61P35/00 ,  C07F9/6571 ,  C07F9/6584 ,  C07F9/655

CPC classification number: C07F9/65685 ,  C07F9/65128 ,  C07F9/65586 ,  C07F9/657181

Abstract: Disclosed are novel quinazoline derivatives containing phosphorus substitutions and methods for the treatment of hyperproliferative diseases (e.g. cancer) using the compounds. These compounds are type I receptor protein kinase inhibitors useful in treating disorders related to abnormal protein kinase activities such as cancer and inflammation in mammals. Also disclosed are pharmaceutical compositions containing the compounds, methods for the preparation of the compounds and their pharmaceutically acceptable salts.

Abstract translation: 公开了含磷取代的新型喹唑啉衍生物和使用该化合物治疗过度增殖性疾病（例如癌症）的方法。 这些化合物是I型受体蛋白激酶抑制剂，可用于治疗与异常蛋白激酶活性相关的疾病，例如哺乳动物的癌症和炎症。 还公开了含有化合物的药物组合物，制备化合物的方法及其药学上可接受的盐。

公开(公告)号：US20090253648A1

公开(公告)日：2009-10-08

申请号：US12415335

申请日：2009-03-31

Applicant: Jesse Daniel Keicher ,  Christopher Don Roberts ,  Sebastian Johannes Reinhard Liehr ,  Xiaoling Zheng ,  Marija Prhavc ,  Vivek Kumar Rajwanshi ,  Ronald Conrad Griffith ,  Choung U. Kim

Inventor： Jesse Daniel Keicher ,  Christopher Don Roberts ,  Sebastian Johannes Reinhard Liehr ,  Xiaoling Zheng ,  Marija Prhavc ,  Vivek Kumar Rajwanshi ,  Ronald Conrad Griffith ,  Choung U. Kim

IPC: A61K31/7064 ,  C07H19/23 ,  A61P31/14

CPC classification number: C07D487/16 ,  C07H19/00 ,  C07H19/22 ,  C07H19/23

Abstract: Disclosed are compounds represented by formulae I, II, and III, and the compositions and methods thereof for treating viral infections caused by a Flaviviridae family virus.

Abstract translation: 公开了由式I，II和III表示的化合物及其用于治疗由黄病毒科家族病毒引起的病毒感染的组合物和方法。

公开(公告)号：US20090048189A1

公开(公告)日：2009-02-19

申请号：US11839380

申请日：2007-08-15

Applicant: Jesse Daniel KEICHER ,  Christopher Don Roberts ,  Sebastian Johannes Reinhard Liehr ,  Xiaoling Zheng ,  Marija Prhavc ,  Vivek Kumar Rajwanshi ,  Ronald Conrad Griffith ,  Choung U. Kim

Inventor： Jesse Daniel KEICHER ,  Christopher Don Roberts ,  Sebastian Johannes Reinhard Liehr ,  Xiaoling Zheng ,  Marija Prhavc ,  Vivek Kumar Rajwanshi ,  Ronald Conrad Griffith ,  Choung U. Kim

IPC: A61K31/7064 ,  C07H19/23 ,  A61P31/14

CPC classification number: C07H19/23

Abstract: Disclosed are tricyclic nucleoside compounds of formula (I), and methods thereof for treating viral infections mediated at least in part by a Flaviviridae family virus.

Abstract translation: 公开了式（I）的三环核苷化合物及其至少部分由黄病毒科家族病毒介导的病毒感染的方法。

公开(公告)号：US09187459B2

公开(公告)日：2015-11-17

申请号：US14118200

申请日：2012-05-17

Applicant: Wang Shen ,  Wei Xiao ,  Jack Maung ,  Aimin Zhang ,  Xiaoling Zheng ,  Zhenzhong Wang ,  Qingming Guo ,  Yingguang Li

Inventor： Wang Shen ,  Wei Xiao ,  Jack Maung ,  Aimin Zhang ,  Xiaoling Zheng ,  Zhenzhong Wang ,  Qingming Guo ,  Yingguang Li

IPC: A01N43/54 ,  A61K31/517 ,  C07D401/00 ,  C07D239/72 ,  C07D405/12 ,  C07D493/04

CPC classification number: C07D405/12 ,  C07D493/04

Abstract: The invention provides quinazoline-7-ether derivatives, particularly 4-anilinyl-6-butenamido-quinazoline-7-ether derivatives that are inhibitors of the receptor protein tyrosine kinases (RTK). The compounds are useful in the treatment of diseases and disorders where RTK activity is implicated such as a hyperproliferative diseases (e.g., cancer). Also provided are methods of preparation of the quinazoline derivatives and methods of use as therapeutic agents alone or in a drug combination.

Abstract translation: 本发明提供了喹唑啉-7-醚衍生物，特别是作为受体蛋白酪氨酸激酶（RTK）抑制剂的4-苯乙烯基-6-丁烯酰氨基 - 喹唑啉-7-醚衍生物。 所述化合物可用于治疗涉及RTK活性的疾病和病症，例如过度增殖性疾病（例如癌症）。 还提供了制备喹唑啉衍生物的方法和单独使用或作为药物组合用作治疗剂的方法。

公开(公告)号：US20120183496A1

公开(公告)日：2012-07-19

申请号：US13328036

申请日：2011-12-16

Applicant: Sam SK Lee ,  Wang Shen ,  Xiaoling Zheng ,  Irina C. Jacobson

Inventor： Sam SK Lee ,  Wang Shen ,  Xiaoling Zheng ,  Irina C. Jacobson

IPC: A61K31/4436 ,  C07D487/04 ,  A61K31/519 ,  C07D417/14 ,  C07D409/14 ,  A61K31/444 ,  A61K31/497 ,  C07D413/14 ,  C07D498/04 ,  C07D471/04 ,  A61K31/4709 ,  A61K38/21 ,  A61K31/7056 ,  A61P31/14 ,  A61K31/4439 ,  C07D409/04

CPC classification number: C07D401/04 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/497 ,  A61K31/519 ,  A61K31/7056 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  C07D401/14 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R1A, R1B, R2, and R3 are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

Abstract translation: 本发明尤其提供由通式I表示的化合物及其药学上可接受的盐，其中X，Y，R 1A，R 1B，R 2和R 3如本文中的类别和亚类所定义，组合物（例如药物 组合物），该化合物可用作丙型肝炎病毒聚合酶的抑制剂，因此可用作例如用于治疗HCV感染的药物。

公开(公告)号：US20060252715A1

公开(公告)日：2006-11-09

申请号：US11365321

申请日：2006-02-28

Applicant: Jesse Keicher ,  Christopher Roberts ,  Sebastian Johannes Liehr ,  Xiaoling Zheng ,  Marija Prhavc ,  Vivek Rajwanshi ,  Ronald Griffith ,  Choung Kim

Inventor： Jesse Keicher ,  Christopher Roberts ,  Sebastian Johannes Liehr ,  Xiaoling Zheng ,  Marija Prhavc ,  Vivek Rajwanshi ,  Ronald Griffith ,  Choung Kim

IPC: A61K31/7076 ,  C07H19/22

CPC classification number: C07D487/16 ,  C07H19/00 ,  C07H19/22 ,  C07H19/23

Abstract: Disclosed are compounds represented by formulae I, II, and III, and the compositions and methods thereof for treating viral infections caused by a Flaviviridae family virus.

公开(公告)号：US09090588B2

公开(公告)日：2015-07-28

申请号：US14002983

申请日：2012-03-02

Applicant: Wang Shen ,  Aimin Zhang ,  Jack Maung ,  Xiaoling Zheng

Inventor： Wang Shen ,  Aimin Zhang ,  Jack Maung ,  Xiaoling Zheng

IPC: C07D405/06 ,  A61K31/517

CPC classification number: C07D405/06 ,  A61K31/517

Abstract: The invention provides alkyne substituted quinazoline compounds, such as compounds of the formula (I), which are irreversible ErbB kinase inhibitors. The compounds are useful in the treatment of diseases and disorders where ErbB kinase activity is implicated such as a hyperproliferative disorder (e.g., cancer).

Abstract translation: 本发明提供炔取代的喹唑啉化合物，例如不可逆ErbB激酶抑制剂的式（I）化合物。 所述化合物可用于治疗涉及ErbB激酶活性的疾病和病症，例如过度增殖性疾病（例如癌症）。

公开(公告)号：US08987284B2

公开(公告)日：2015-03-24

申请号：US13380808

申请日：2010-07-02

Applicant: Wang Shen ,  Aimin Zhang ,  Junfa Fan ,  Xiaoling Zheng

Inventor： Wang Shen ,  Aimin Zhang ,  Junfa Fan ,  Xiaoling Zheng

IPC: A01N43/54 ,  A61K31/517 ,  C07D239/72 ,  C07D401/00 ,  C07F9/6512 ,  C07F9/6558 ,  C07F9/6568 ,  C07F9/6571

CPC classification number: C07F9/65685 ,  C07F9/65128 ,  C07F9/65586 ,  C07F9/657181

Abstract: Disclosed are novel quinazoline derivatives containing phosphorus substitutions and methods for the treatment of hyperproliferative diseases (e.g. cancer) using the compounds. These compounds are type I receptor protein kinase inhibitors useful in treating disorders related to abnormal protein kinase activities such as cancer and inflammation in mammals. Also disclosed are pharmaceutical compositions containing the compounds, methods for the preparation of the compounds and their pharmaceutically acceptable salts.

Abstract translation: 公开了含磷取代的新型喹唑啉衍生物和使用该化合物治疗过度增殖性疾病（例如癌症）的方法。 这些化合物是I型受体蛋白激酶抑制剂，可用于治疗与异常蛋白激酶活性相关的疾病，例如哺乳动物的癌症和炎症。 还公开了含有化合物的药物组合物，制备化合物的方法及其药学上可接受的盐。

公开(公告)号：US20140128417A1

公开(公告)日：2014-05-08

申请号：US14002983

申请日：2012-03-02

Applicant: Wang Shen ,  Aimin Zhang ,  Jack Maung ,  Xiaoling Zheng

Inventor： Wang Shen ,  Aimin Zhang ,  Jack Maung ,  Xiaoling Zheng

IPC: C07D405/06

CPC classification number: C07D405/06 ,  A61K31/517

Abstract: The invention provides alkyne substituted quinazoline compounds, such as compounds of the formula (I), which are irreversible ErbB kinase inhibitors. The compounds are useful in the treatment of diseases and disorders where ErbB kinase activity is implicated such as a hyperproliferative disorder (e.g., cancer).

Abstract translation: 本发明提供炔取代的喹唑啉化合物，例如不可逆ErbB激酶抑制剂的式（I）化合物。 所述化合物可用于治疗涉及ErbB激酶活性的疾病和病症，例如过度增殖性疾病（例如癌症）。